<DOC>
	<DOCNO>NCT00726869</DOCNO>
	<brief_summary>This Phase 1/2 , multi-center , open-label , multiple-dose , dose escalation study evaluate combination elotuzumab bortezomib subject MM follow 1 3 prior therapy . For Phase 1 portion , elotuzumab administer intravenous ( IV ) infusion 4 dose level range 2.5 mg/kg 20.0 mg/kg within 30 minute follow administration bortezomib 1.3 mg/m^2 IV bolus . Bortezomib give 21 day cycle ( twice weekly 2 week Days 1 , 4 , 8 , 11 follow 10-day rest period ) . Elotuzumab administer separate infusion within 30 minute follow bortezomib administration day first last dose bortezomib cycle ( i.e. , Days 1 11 ) .</brief_summary>
	<brief_title>A Phase 1/2 , Multi-center , Open-label , Dose-escalation Study Elotuzumab ( Humanized Anti-CS1 Monoclonal IgG1 Antibody ) Bortezomib Subjects With Multiple Myeloma Following One Three Prior Therapies .</brief_title>
	<detailed_description>The phase 2 portion study initiate decision make conduct phase 2 randomized clinical trial .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Inclusion Criteria 1 . Males female , age 18 year old . 2 . Diagnosis MM documentation 1 3 prior therapy . 3 . Mprotein spike ( complete immunoglobulin molecule ) &gt; = 1g/dL serum and/or &gt; = 0.5 g excrete 24hour urine collection sample . Light chain disease inclusion criterion . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 5 . No prior bortezomib treatment OR responsive ( PR well ) prior bortezomib treatment minimum 3 month OR responsive prior bortezomib treatment time go another treatment cease treatment . 6 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; =3 x upper limit normal ( ULN ) . 7 . Total bilirubin &lt; =2 x ULN . 8 . Serum creatinine &lt; =2.0 mg/dL ( unless relate MM , &lt; =3.0 mg/dL ) . 9 . Must adequate bone marrow function define : Absolute neutrophil count &gt; 1,000 cells/mm3 ( 1.0 x 10^9 cells/L ) without growth factor support 7 day ; Platelets &gt; =75,000 cells/mm3 ( 75 x 10^9 cells/L ) without transfusion within 72 hour screen ; Hemoglobin &gt; =8 g/dL without red blood cell transfusion within 2 week screen ; 10 . Serum calcium ( correct albumin ) level ULN range ( treatment hypercalcemia allow subject may enroll hypercalcemia return normal standard treatment ) ; additional screening time may allow confirmation consult sponsor 's medical monitor . 11 . Use appropriate contraception applicable . 12 . Negative urine pregnancy test applicable . 13 . Must 2dimensional echocardiogram indicating leave ventricular ejection fraction ( LVEF ) &gt; =45 % within 30 day prior first dose elotuzumab . 14 . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( accordance national local subject privacy regulation ) . Exclusion Criteria 1 . Life expectancy le 3 month . 2 . Prior malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer subject diseasefree least 2 year . 3 . Uncontrolled medical problem diabetes mellitus , coronary artery disease , hypertension , unstable angina , arrhythmia , pulmonary , ( include acute diffuse infiltrative pulmonary pericardial disease ) , hepatic , renal disease unless renal insufficiency felt secondary MM . 4 . Solitary bone solitary extramedullary plasmacytoma evidence plasma cell dyscrasia . 5 . Prior treatment bortezomib 3 month prior first dose . 6 . Thalidomide , lenalidomide cytotoxic chemotherapy , corticosteroid ( except prior infusion first dose study drug prophylaxis infusion reaction ) within 2 week first dose elotuzumab . 7 . Prior therapy antiCD56+ therapeutic . 8 . Radiotherapy within 2 week prior first dose elotuzumab . 9 . Investigational drug within 3 week 3x halflife investigational drug ( whichever longer ) first dose elotuzumab . 10 . Prior peripheral stem cell transplant within 12 week first dose elotuzumab . 11 . Nitrogen mustard agent , melphalan , monoclonal antibody within 6 week first dose elotuzumab . 12 . Neuropathy &gt; =Grade 2 ( NCI CTCAE v3.0 ) . 13 . Current orthostatic hypotension . 14 . Known active infection require antibiotic , antiviral , antifungal therapy . 15 . Serious psychiatric illness , active alcoholism , drug addiction may hinder confuse followup evaluation . 16 . Any condition investigator 's opinion make subject unsuitable study participation . 17 . Hypersensitivity recombinant proteins excipients elotuzumab bortezomib .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Patients After One three Prior Therapies</keyword>
</DOC>